Industry
Biotechnology
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 9:10 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 9:09 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 9:49 am
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
December 11, 2023 | 3:21 pm
Portfolio Pulse from Benzinga Newsdesk
December 07, 2023 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
November 21, 2023 | 9:29 pm
Portfolio Pulse from Vandana Singh
November 08, 2023 | 6:20 pm
Portfolio Pulse from Lisa Levin
November 08, 2023 | 4:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.